Mouse mast cells express gp49Bl, a cellsurface member of the Ig superfamily encoded by the gp49B gene. We now report that by ALIGN comparison of the amino acid sequence of gp49B1 with numerous receptors of the Ig superfamily, a newly recognized family has been established that includes gp49B1, the human myeloid cell Fc receptor for IgA, the bovine myeloid cell Fc receptor for IgG2, and the human killer cell inhibitory receptors expressed on natural killer cells and T lymphocyte subsets. Furthermore, the cytoplasmic domain of gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs that are also present in killer cell inhibitory receptors; these motifs downregulate natural killer cell and T-cell activation signals that lead to cytotoxic activity. As assessed by flow cytometry with transfectants that express either gp49B1 or gp49A, which are 89% identical in the amino acid sequences of their extracellular domains, mAb B23.1 was shown to recognize only gp49B1. Coligation of mAb B23.1 bound to gp49B1 and IgE fixed to the high-affinity Fc receptor for IgE on the surface of mouse bone marrow-derived mast cells inhibited exocytosis in a dose-related manner, as defined by the release of the secretory granule constituent f3-hexosaminidase, as well as the generation of the membranederived lipid mediator, leukotriene C4. Thus, gp49B1 is an immunoreceptor tyrosine-based inhibition motif-containing integral cell-surface protein that downregulates the highaffinity Fc receptor for IgE-mediated release of proinflammatory mediators from mast cells. Our findings establish a novel counterregulatory transmembrane pathway by which mast cell activation can be inhibited.
The rat mAb B23.1 recognizes an epitope expressed on an -49-kDa glycoprotein on the surface of mouse mast cells, which is synthesized from an intracellular 37-kDa protein precursor (1) . Immunoaffinity purification of a cell-surface protein from mast cells with mAb B23.1, determination of its amino terminal amino acid sequence, and screening of a mast cell cDNA library with oligonucleotides encoding the amino terminal sequence provided three cDNAs that encode this amino terminal amino acid sequence (2, 3) . One of these (gp49B1) predicts a 35-kDa protein core that contains two C2-type, Ig-like domains in the extracellular region (3) . The expression of the gp49B1 cDNA in COS transfectants confers binding of mAb B23.1, indicating that the mAb recognizes an epitope present on gp49B1 (3) . One of the other cDNAs (gp49A), isolated in the same screen, predicts a 32-kDa protein core that has two C2-type, Ig-like domains in its extracellular region and is 89% identical at the amino acid level to gp49B1. gp49A also has 100% amino acid identity with gp49B1 in the transmembrane domain and 88% identity in the first 34 amino acids of the cytoplasmic domain. The cytoplasmic region of gp49A then diverges for 8 amino acids because of a frameshift in the nucleotide sequence and terminates so that it is 32 amino acids shorter than gp49B1. Whether the specificity of the epitope recognized by mAb B23.1 is limited to gp49B1 as compared with gp49A had not been previously established.
When B lymphocytes are exposed to F(ab')2 fragments of anti-membrane Ig antibody, a signal transduction cascade is elicited through the B-lymphocyte antigen receptor that results in B-lymphocyte proliferation and differentiation into antibody-secreting cells (4, 5) . In contrast, stimulation with intact anti-membrane Ig results in attenuated B-lymphocyte signal transduction, as measured by the influx of extracellular calcium (6) and levels of cellular inositol trisphosphates (7) . The fact that the suppression of B-cell stimulation can be prevented by blocking the binding of intact anti-membrane Ig to Fc receptors for IgG, type Ilbl (FcyRIIbl) on the B lymphocyte (4, 8) , indicates that coligation of the B-lymphocyte antigen receptor with FcyRIIbl inhibits B-lymphocyte stimulation. Amino acid substitution experiments revealed that a 13-amino acid region of the cytoplasmic domain of FcyRIIbl is sufficient to inhibit B-lymphocyte stimulation (8) . Furthermore, a tyrosine in the 13-amino acid sequence is phosphorylated during coligation of the two receptors, and the mutation of this tyrosine to phenylalanine prevents the FcyRIIbl-mediated inhibition of B lymphocyte activation (8 (10) . In a rat mast cell line transfected with mouse Fc,yRIIb2, coligation of the mouse receptor with endogenous rat FceRI-inhibited exocytosis and the secretion of tumor necrosis factor-a (10). Simultaneous, independent ligation of Fc,yRIIb2 and FcsRI did not inhibit exocytosis in the transfectants, nor did coligation when the cytoplasmic domain of the FcyRII species was deleted. Thus, the apposition of cytoplasmic domain sequences in Fc-yRIIb species with FcsRI down-regulates mast cell activation.
Human natural killer (NK) cells and T-lymphocyte subsets express a group of Ig superfamily cell surface receptors, termed "killer cell inhibitory receptors" (KIRs) that recognize allelic groups of the major histocompatibility complex class I molecules (11) (12) (13) (14) (15) . The engagement of KIRs by the appropriate major histocompatibility complex class I molecules inhibits the activation pathways of both NK cells and T lymphocytes for cytotoxic effector function (13, 14, 16, 17, 18) , and this recognition mechanism protects normal, autologous cells. Both the KIRs and the Fc-yRIIb species contain a core consensus motif in their cytoplasmic domains, INVxYxxL/V termed the immunoreceptor tyrosine-based inhibition motif (ITIM) (19, 20) ; the ITIM core is within the 13-amino acid region of the FcyRIIb species that mediates inhibition of B-lymphocyte stimulation. Phosphorylated, but not nonphosphorylated, peptides containing ITIMs from KIR cytoplasmic domains interact with and stimulate SHP-1 activity (19, 20) . Moreover, the transfection of cytolytic, KIR-deficient NK cells exhibiting low levels of SHP-1 with constructs encoding a KIR and active SHP-1 inhibits their cytotoxicity for an appropriate target cell, whereas cotransfection with a construct encoding the KIR and enzymatically inactive SHP-1 does not. Thus, the recruitment of SHP-1 activity is directly involved in KIRmediated inhibition of NK cell cytotoxicity (19 (21) , and a similarity score was derived with the Dayhoff cost matrix (22) , with a cost of 6 for opening a gap (23) and an incremental cost of 0.5 for each residue in the gap. To determine the significance of the similarity score, the sequence being compared with gp49B1 was then randomized 100 times, and the gp49B1 sequence was aligned with each randomized sequence. The means (± SD) of the resulting similarity scores were calculated. To determine the significance of the original comparison, its similarity score was subtracted from the mean score of the randomized comparisons and the result was divided by the SD of the randomized comparisons to obtain the ALIGN score (21) . Scores -3 indicate that the similarities between the compared sequences are significantly greater than would occur by chance alone (23) .
Generation of mBMMC and Stable gp49 Transfectants in P815 Cells. Bone marrow cells from male BALB/c mice (The Jackson Laboratory) were cultured for 3-7 weeks in enriched medium containing 50% WEHI-3 cell conditioned medium (WCM) (American Type Culture Collection) as described (24) . After 3 weeks, >97% of the nonadherent cells in the cultures were mast cells as assessed by metachromatic staining with toluidine blue (25) .
To prepare transfectants, gp49A and gp49B1 cDNAs were subjected to PCR with primers whose sequences matched nucleotides 22-42 (5'-CGAACATTGCCTGGACTCACC-3'; 5' untranslated region) and 1287 to 1306 (5'-GTTTCTCAT-TAGATGACTTG-3'; 3' untranslated region) that are common to the gp49A and gp49B1 cDNAs (3). The 5' ends of the upstream and downstream primers contained XbaI and BamHI linkers, respectively, to facilitate ligation into the mammalian expression vector, pMH-NEO (26) . PCR was performed for 30 cycles with primer annealing at 60°C. After ligation of the amplified cDNAs into pMH-NEO, DH5a bacterial cells (Stratagene) were transformed either with pMH-NEO alone or with pMH-NEO containing gp49A cDNA or gp49Bl cDNA. Plasmid DNA containing the vector alone or with the inserted cDNAs was purified with Nucleobond AX (The Nest Group, Southborough, MA) and introduced into P815 cells by electroporation with 200 mV and 960 ,uF in a Bio-Rad Gene Pulser Electroporator. Stable transfectants were selected by their resistance to 1.2 mg/ml of G418.
After -6 weeks of culture, gp49B1 transfectants were stained with mAb B23.1 and F(ab')2 fragments of fluorescein isothiocyanate (FITC)-labeled goat anti-rat IgM (Jackson ImmunoResearch). The cells were sorted, and the 1% brightest cells were collected and cloned by being seeded in 96-well plates at an average density of 0.3 cell per well. After 7 days, the plates in which cells were growing in fewer than 30% of the wells were analyzed by flow cytometry for binding of mAb B23.1. Five clones exhibited similar or stronger staining with mAb B23.1 compared with BMMC, and one such clone (1-11G) was chosen for study.
For identification of gp49A transfectants, total RNA was isolated from stable P815 clones that had been transfected with gp49A cDNA, and the presence of gp49A transcripts was detected by reverse transcriptase (RT)-PCR. For the RT step, a downstream primer located in exon 6 of gp49A was used (5'-TAGCCTTATTTTTGTGACGAC-3'). PCR was performed on the resultant cDNAs with the same downstream primer plus an upstream primer from exon 3 of gp49A (5'-ACCAAGTTCAAAATTCGATTT-3'); an annealing temperature of 60°C was used for 40 cycles. These primers were specific for gp49A because they generated a product by RT-PCR from COS-7 cells transiently transfected with a gp49A, but not gp49B1, cDNA (data not shown). Anti-gp4972-87 IgG was purified on peptide-affinity columns. Each peptide (10 mg) was coupled to 1 mg of cyanogen bromide-activated Sepharose 4B (Pharmacia LKB), according to the manufacturer's protocol. An 8-ml sample of antigp4972-87 serum was applied to a column containing 2 ml of resin coupled with the heterologous gp49B172-87 peptide, and the flow-through was applied to a column containing the homologous peptide. The second column was washed sequentially with 20 column vol of 10 mM Tris-HCl (pH 7.5), 20 column vol of 500 mM NaCl in 10 mM Tris HCl (pH 7.5), and 20 column vol of 10 mM Tris HCl (pH 7.5). Ig was then eluted with 2 column vol of 100 mM glycine (pH 2.5) into 0. (Fig. 1) . Delineation of the two groups of proteins was also observed when each Ig-like domain of gp49, including 20 amino acids flanking each end (23), was compared by ALIGN analysis with molecules representative of the set shown in Fig. 1 (32) with default settings to generate the tree. The segregation of the mouse gp49, bovine Fcy2R, and human FcaR and KIR proteins into a family distinct from the other receptors was confirmed in the analysis because their branches localized as a group that radiated -180°away from the branches that contained the other receptors analyzed (data not shown).
Analysis of the Binding Specificity of mAb B23.1 for gp49Bl and gp49A. Stable transfectants that express gp49A or gp49B1 were generated in the mouse P815 mastocytoma cell line, which binds little or no mAb B23.1 (33) . As determined by flow cytometry, mAb B23.1 bound to gp49B1, but not gp49A, transfectants as compared with background binding to P815 cells transfected with the pMH-NEO expression vector alone (Fig. 2) . In contrast, anti-gp49A72m87 IgG bound to gp49A, but not gp49B1 transfectants, thereby demonstrating that gp49A was expressed on the surface of the appropriate transfectants. Thus, it is reasonable to assume that cell-surface gp49B1 can be selectively bound by mAb B23.1 on nontransfected cells, such as mBMMC.
Effects of Ligation of gp49Bl and FceRI on Mast Cell Activation. The cytoplasmic domain of gp49B1 contains two sequences that conform to the ITIM consensus (20) , namely, IVYAQV and VTYAQL (3). To determine whether coligation of gp49B1 with FcERI altered activation-secretion, mBMMC were incubated at 4°C with rat IgE (3 ,ug/ml) alone or together with the RATNP 17.3 isotype control (20 ,ug/ml) or incremental concentrations of mAb B23.1 (0.625-20 gg/ ml). Samples of cells were also incubated with RATNP 17.3 or mAb B23.1 alone. The cells were washed once and incubated for 15 min at 37°C in medium either alone or with the coligating antibody, a F(ab')2 mouse IgG that is reactive with the light chains of rat IgE and IgM. No release of the secretory granule mediator ,B-hexosaminidase occurred unless mBMMC were primed with rat IgE in the first step and then stimulated with the second antibody (Fig. 3A) . The release of f3-hexosaminidase was inhibited in a dose-dependent fashion when mBMMC were concomitantly incubated with the fixed concentration of rat IgE and incremental concentrations of mAb B23.1 before coligation of their respective FcsRI and gp49B1 molecules. The release of LTC4 was inhibited in a similar manner (Fig. 3B ).
DISCUSSION
We have established that the coligation of gp49B1 with FcsRI inhibits mast cell activation-responses. The recognition that gp49B1 might be an inhibitory protein initially arose from ALIGN analysis of the amino acid sequences of gp49B1 versus other members of the Ig superfamily containing two C2-type, Ig-like domains. This analysis revealed statistically significant homology between gp49B1 and human KIRs. There was also homology between gp49B1, human FcaR, and bovine Fcy2R, but not with other Fc-yR species or FceRI of the human and mouse (Fig. 1) . The segregation of the homologous proteins into a distinct family was supported by separate evolutionary tree analysis (data not shown) (31, 32) . A second finding suggested a basis for a function for gp49B1, namely, suppression of an activation event in mast cells, because the cytoplasmic domain possessed two ITIMs, a motif that is also recognized in FcyRIIb species and in KIRs of NK cells and T-lymphocyte subsets. Moreover, although the cytoplasmic domain of mouse Fc-yRIIbl contains only one ITIM, coligation of this Fc receptor with the B-lymphocyte antigen receptor or with FceRI inhibits B lymphocyte and mast cell activation, respectively (8) (9) (10) . Of note is the finding that mouse gp49B1 does not exhibit statistically significant amino acid sequence homology with mouse Fc-yRIIbl (Fig. 1) . Thus, our findings establish that separate homology-defined families within the Ig superfamily, with possibly distinct counterligands, inhibit mast cell activation.
We previously demonstrated that COS cells transfected with a cDNA encoding gp49B1 are immunoreactive with mAb B23.1 (3) . However, the specificity of the mAb with regard to gp49A was unknown because of the 89% identity between the extracellular domains of gp49B1 and gp49A. To address this issue, stable transfectants expressing either the gp49A or the gp49B1 cDNA were created in the P815 mastocytoma cell line, which binds little or no mAb B23.1 (Fig. 2) . In addition, to measure specifically the expression of gp49A in transfectants, rabbit anti-gp49A72-87 IgG was prepared to a peptide in the extracellular domain that differs in gp49A and gp49B1 (3). ) were measured by spectrophotometric assay and radioimmunoassay, respectively. ,3-hexosaminidase data are expressed as mean ± SEM, n = 4; LTC4 data are expressed as mean + half-range, n = 2. The net percent of 13-hexosaminidase release and LTC4 release when control rat IgM mAb RATNP 17.3 (20 pug/ml) was combined with the rat IgE sensitization step before coligation are indicated (*) and were not appreciably different from the mediator release from cells incubated with rat IgE alone. The percent of ,B-hexosaminidase release when cells were exposed to RATNP 17.3 alone and then to either medium or F(ab')2 mouse IgG anti-rat IgG in the second step was 8 ± 4% and 3 ± 1%, respectively (n = 3); release values for cells that were exposed to mAb B23.1 alone (20 ,ug/ml) in the first step were 7 ± 3% and 4 ± 2%, respectively (n = 4). Release of LTC4 under these conditions was undetectable.
gp49B1, and anti-gp4972-87 IgG specifically bound to gp49A transfectants (Fig. 2) . Because mAb B23.1 recognizes cellsurface gp49B1, but not gp49B1 after exposure to SDS (data not shown), mAb B23.1 appears to recognize a conformationdependent, gp49B1-specific epitope within an extracellular domain that is 89% identical to that of gp49A. The latter finding is reminiscent of the fact that certain anti-human KIR mAbs specifically recognize individual receptor species, even though their extracellular domains differ only by several scattered amino acids (30) .
With use of BMMC primed with rat IgM mAb B23.1 anti-gp49B1 and rat IgE, the effects of coligation of gp49B1 and FcsRI were established with a second antibody, namely, F(ab')2 mouse IgG anti-rat IgG. This antibody recognized the light chains of both rat mAb B23.1 and rat IgE, as assessed by flow cytometry (data not shown). Neither mAb B23.1 nor the isotype-matched mAb RATNP 17.3 alone elicited the release of mediators from mBMMC after exposure to second antibody ( Fig. 3 A and B) . However, when mAb B23.1 and rat IgE on the surface of the mast cells were coligated with the second antibody, a mAb B23.1-dependent, dose-related inhibition of ,3-hexosaminidase (Fig. 3A) and LTC4 (Fig. 3B) release occurred. This inhibition was not the result of a limitation in the amount of F(ab')2 mouse IgG anti-rat IgG available to react with FcsRI, because both the rat IgE and mAb B23.1 were added to the cells at concentrations that were not saturating for the binding of second antibody, as determined by flow cytometry (data not shown). The finding that gp49B1 contains two core ITIM motifs and suppresses secretory granule and lipidderived mediator release when coligated with FcsRI leads us to propose that gp49B1 be designated "mouse mast cell inhibitory receptor" (mMIR).
The mechanism by which ITIMs inhibit cellular activation events appears to be through the downstream recruitment of one or more tyrosine phosphatases that reverse a tyrosine phosphorylation step(s) critical to progressive signal transduction. Coligation of the B-lymphocyte antigen receptor with FcyRIIbl causes tyrosine phosphorylation of each receptor with different resultant intracellular protein associations. Whereas the B-lymphocyte antigen receptor associates with syk kinase via the receptor's immunoreceptor tyrosinecontaining activation motif in the Ig-a and Ig-,B subunits (8) , phosphopeptides encompassing the FcyRIIB1 ITIM bind SHP-1 (9) . Furthermore, tyrosine-phosphorylated KIR peptides from the two ITIMs of certain human KIRs bind SHP-1 and SHP-2 [formerly PTP1D] (19, 20) . Thus, ITIMs may mediate inhibitory effects by recruiting tyrosine phosphatases that could reverse and/or suppress tyrosine phosphorylation events at one or more steps of signal transduction cascades that activate cellular functions.
The finding that mMIR is homologous to members of the Ig superfamily that bind other members of the superfamily (e.g., Fc receptors/Ig, KIRs/major histocompatibility complex class I molecules) suggests that its counterligand may also be a member of the Ig superfamily. Although mouse NK cells express a family of KIRs (Ly49) that contain the ITIM motif (20) and function like human NK cell KIRs in interacting with major histocompatibility complex class I molecules, the Ly49 family consists of type II transmembrane proteins with an extracellular C-type lectin domain, rather than an Ig-like structure (14) . It is possible therefore, based on the structural and functional considerations presented here, that mMIR may belong to a family of molecules that are the mouse equivalents of human NK and T-lymphocyte KIRs.
